Comments on: Requiring the HPV Vaccine for Public School Attendance—Considerations & Concerns http://schoolhealthblog.org/2007/schools-requiring-hpv-vaccine/ Blog of the American School Health Association Thu, 29 Jul 2010 20:34:14 +0000 http://wordpress.org/?v=2.3 By: laniwheeler http://schoolhealthblog.org/2007/schools-requiring-hpv-vaccine/#comment-28 laniwheeler Wed, 10 Sep 2008 20:04:21 +0000 http://schoolhealthblog.org/2007/schools-requiring-hpv-vaccine/#comment-28 More new information: Vaccines and Preventable Diseases: HPV Vaccine - Cost-Effectiveness of HPV Vaccine August 28, 2008 CDC Statement on the Cost-Effectiveness of HPV Vaccine There has been recent media attention related to a study of the cost effectiveness of human papillomavirus (HPV) vaccination in the United States published in the New England Journal of Medicine on August 21, 2008. This study confirms the cost-effectiveness of HPV vaccination of 11and12 year old girls and is consistent with the main focus of the CDC’s recommendations which call for routine HPV vaccination of 11 and 12 year old girls in the United States. The HPV vaccine is highly effective in preventing four types of HPV in young women who have not been previously exposed to HPV. The vaccine targets HPV types that cause up to 70% of all cervical cancers and about 90% of genital warts. It is clear that vaccinating women in their mid-to-late twenties is not as cost-effective as vaccinating 11 and 12-year-old girls. However, the majority of girls and women 13 through 26 years of age also can benefit from vaccination. Ideally, HPV vaccine should be administered before sexual debut. Females 13 through 26 years of age who are not yet sexually active can be expected to receive the full benefit of vaccination. Studies suggest that while sexually active females in this age group might have been infected with one or more vaccine HPV types, only a small percentage have been infected with all four of the HPV vaccine types. Females already infected with one or more HPV vaccine types before vaccination would be protected against disease caused by the other HPV vaccine types. Therefore, the majority of females in this age group will derive benefit from vaccination. See more at: http://www.cdc.gov/vaccines/vpd-vac/hpv/cost-effect-hpv-vac.htm Lani Wheeler More new information:
Vaccines and Preventable Diseases:
HPV Vaccine - Cost-Effectiveness of HPV Vaccine
August 28, 2008

CDC Statement on the Cost-Effectiveness of HPV Vaccine

There has been recent media attention related to a study of the cost effectiveness of human papillomavirus (HPV) vaccination in the United States published in the New England Journal of Medicine on August 21, 2008. This study confirms the cost-effectiveness of HPV vaccination of 11and12 year old girls and is consistent with the main focus of the CDC’s recommendations which call for routine HPV vaccination of 11 and 12 year old girls in the United States. The HPV vaccine is highly effective in preventing four types of HPV in young women who have not been previously exposed to HPV. The vaccine targets HPV types that cause up to 70% of all cervical cancers and about 90% of genital warts.

It is clear that vaccinating women in their mid-to-late twenties is not as cost-effective as vaccinating 11 and 12-year-old girls. However, the majority of girls and women 13 through 26 years of age also can benefit from vaccination. Ideally, HPV vaccine should be administered before sexual debut. Females 13 through 26 years of age who are not yet sexually active can be expected to receive the full benefit of vaccination. Studies suggest that while sexually active females in this age group might have been infected with one or more vaccine HPV types, only a small percentage have been infected with all four of the HPV vaccine types. Females already infected with one or more HPV vaccine types before vaccination would be protected against disease caused by the other HPV vaccine types. Therefore, the majority of females in this age group will derive benefit from vaccination.

See more at: http://www.cdc.gov/vaccines/vpd-vac/hpv/cost-effect-hpv-vac.htm

Lani Wheeler

]]> By: laniwheeler http://schoolhealthblog.org/2007/schools-requiring-hpv-vaccine/#comment-26 laniwheeler Wed, 20 Aug 2008 16:04:25 +0000 http://schoolhealthblog.org/2007/schools-requiring-hpv-vaccine/#comment-26 Here's an excellent new paper. A Critique of Criteria for Evaluating Vaccines for Inclusion in Mandatory School Immunization Programs Douglas J. Opel, Douglas S. Diekema, and Edgar K. Marcuse Pediatrics 2008; 122: e504-e510 Several new vaccines for children and young adults have been introduced recently and now appear on the Advisory Committee on Immunization Practices’ recommended childhood and adolescent immunization schedule (meningococcal, rotavirus, human papillomavirus). As new vaccines are introduced, states face complex decisions regarding which vaccines to fund and which vaccines to require for school or child care entry. This complexity is evidenced by the current debate surrounding the human papillomavirus vaccine. We present a critique to the approach and criteria for evaluating vaccines for inclusion in mandatory school immunization programs that have been adopted by the Washington State Board of Health by illustrating how these criteria might be applied to the human papillomavirus vaccine. We conclude that these 9 criteria can help ensure a deliberate and informed approach to important public policy decisions, but we argue that several clarifications of the review process are needed along with the addition of a 10th criterion that ensures that a new vaccine mandate relates in some manner to increasing safety in the school environment. Here’s an excellent new paper.
A Critique of Criteria for Evaluating Vaccines for Inclusion in Mandatory School Immunization Programs
Douglas J. Opel, Douglas S. Diekema, and Edgar K. Marcuse
Pediatrics 2008; 122: e504-e510
Several new vaccines for children and young adults have been introduced recently and now appear on the Advisory Committee on Immunization Practices’ recommended childhood and adolescent immunization schedule (meningococcal, rotavirus, human papillomavirus). As new vaccines are introduced, states face complex decisions regarding which vaccines to fund and which vaccines to require for school or child care entry. This complexity is evidenced by the current debate surrounding the human papillomavirus vaccine. We present a critique to the approach and criteria for evaluating vaccines for inclusion in mandatory school immunization programs that have been adopted by the Washington State Board of Health by illustrating how these criteria might be applied to the human papillomavirus vaccine. We conclude that these 9 criteria can help ensure a deliberate and informed approach to important public policy decisions, but we argue that several clarifications of the review process are needed along with the addition of a 10th criterion that ensures that a new vaccine mandate relates in some manner to increasing safety in the school environment.

]]>